Navigation Links
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

BIRMINGHAM, Ala., Dec. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) announced today that the Company will present pre-clinical data on Forodesine HCl and BCX-4208, and clinical data on BCX-4208 at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition being held in San Francisco, CA from December 6-9, 2008. Forodesine HCl and BCX-4208 are clinical-stage purine nucleoside phosphorylase (PNP) inhibitors.

The schedule for BioCryst's poster presentations at ASH is as follows:

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active Anti T- and B-Cell Agent (Poster # 1547)

Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects (Poster # 2583)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells (Poster # 1925)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value.

The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.


SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
2. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
3. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
4. BioCryst to Present at the JMP Healthcare Focus Conference
5. BioCryst to Present at UBS 2008 Global Life Sciences Conference
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
8. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
9. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... ... 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem ... from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the early ... is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of ...
(Date:10/7/2015)... N.Y. , Oct. 7, 2015   PDI ... today released an infographic that highlights key challenges across ... an appropriate disinfectant for the situation. This tool is ... steps hospitals can take to create efficiencies and lower ... The visual guide emphasizes examples of how to ...
Breaking Biology Technology:
... the people who helped North Carolina and Los Angeles ... communities of angel investors shared their most effective practices ... , ,Their techniques included educational programsbut you have to ... of the Council for Entrepreneurial Development , based ...
... Educating and advising potential angel investors, or cherubs, ... seraphs was the goal of a seminar at the ... titled Private Equity and Angel Investing Boot Camp, exposed ... resources and initiatives customized to help burgeoning investors make ...
... new leading security solution that combines networking infrastructure and ... approach to security. It is a logical step in ... imperatives from an IT perspective have been focused on ... components of network security. But more recently, with an ...
Cached Biology Technology:
(Date:9/8/2015)... 8, 2015  Affectiva, global leader in emotion-sensing ... Service, a new data solution, and version 2.0 ... Affectiva,s highly accurate and patented science, these new ... to transform industries such as market research, gaming, ... experience, online education, HR, automotive, robotics, healthcare and ...
(Date:9/2/2015)... 2, 2015 Security of data and ... banks, government organizations, telecommunications, hospitals, as well as ... previously being used to prevent unauthorised access. Technological ... wherein individuals could gain access to secure premises ... as hardware devices and numeric codes. However, hackers ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
Breaking Biology News(10 mins):
... one of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . A ... Bioengineering and Biotechnology will provide a single open-access ... to be disseminated and discussed. Frontiers ...
... U.S. Forest Service scientists are part of "Landscapes ... the TKF Foundation, will examine how collaborative planning and ... from tragedy. , The TKF Foundation announced today that ... for grant funding. In addition to research on the ...
... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ...
Cached Biology News:
... The 7500ce meets the demands of ... require high performance from reliable, robust and ... unmatched detection power in the most challenging ... It is equally suited to the toughest ...
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... LC Sciences provides a comprehensive ... small regulatory/functional RNA embedded within non-coding ... technology and proprietary probe design, which ... detection of small RNAs (1). This ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: